Table 2. The relationship between clinicopathological characteristics, nuclear p-p65 and cancer-specific survival in patients with invasive ductal breast cancer.

	Univariate analysis		Multivariate analysis Nuclear p-p65		Multivariate analysisTotal tumour cell p-p65
Patients (n=376)	Hazard ratio(95% CI)	P value	Hazard ratio(95% CI)	P value	Hazard ratio(95% CI)	P value
Age (≤50/ >50 years)	1.33(0.812-2.24)	0.248
Size (≤20/ 21-50/ >50 mm)	1.72(1.16-2.56)	0.007
Grade (I / II / III)	1.94(1.37-2.75)	<0.001
Involved lymph node (no/yes)	3.34(2.04-5.47)	<0.001	2.39(1.40-4.07)	0.001	2.13(1.23-3.68)	0.007
ER status (no/yes)	0.46(0.29-0.72)	0.001
PR status (no/yes)	0.37(0.22-0.61)	<0.001	0.43(0.25-0.730)	0.002	0.44(0.25-0.74)	0.002
HER2 status (no/ yes)	2.15(1.33-3.48)	0.002
Tumour necrosis (low/high)	4.33(2.41-7.94)	<0.001	3.71 (1.97-6.97)	<0.001	3.51(1.90-6.74)	<0.001
Lymph vessel invasion (no/yes)	3.59(2.28-5.66)	<0.001
Blood vessel invasion (no/yes)	3.01(1.79-5.06)	<0.001	2.42(1.38-4.24)	0.002	2.19(1.23-3.90)	0.007
Klintrup–Mäkinen grade (week/strong)	1.32(0.82-2.13)	0.249
CD68+ (low/moderate/high)	0.78(0.59-1.04)	0.093
CD4+ (low/moderate/high)	1.00(0.782-1.28)	0.938
CD8+ (low/moderate/high)	0.62(0.46-0.82)	0.001	0.54(0.40-0.74)	<0.001	0.54(0.40-0.72)	<0.001
CD138+ (low/moderate/high)	1.36(1.07-1.73)	0.01	1.461.11-1.91)	0.005	1.41(1.09-1.87)	0.009
Tumour stroma percentage (low/high)	1.26(1.44-3.54)	<0.001	2.12(1.32-3.41)	0.002	2.10(1.30-3.38)	0.002
Tumour budding (low/high)	2.45(1.57-3.82)	<0.001	2.12(1.31-3.42)	0.002	1.79(1.07-2.97)	0.025
Nuclear p-p65 (low/high)	1.29(1.00-1.67)	0.045	1.31(0.99-1.73)	0.057	NA	NA
Total Tumour cell p-p65 (both low/ one high)	1.21(1.02-1.44)	0.029	NA	NA	1.25(1.03-1.53)	0.024